{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T15:18:08Z","timestamp":1793373488849,"version":"4.5.0"},"reference-count":25,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Otolaryngol Head Neck Surg"],"published-print":{"date-parts":[[2025,7,1]]},"abstract":"<jats:sec><jats:title>Importance<\/jats:title><jats:p>The De-escalated Adjuvant Radiation Therapy (DART) phase 3 randomized clinical trial (RCT) showed that in patients with human papillomavirus (HPV)\u2212associated oropharyngeal squamous cell carcinoma, postoperative minimal residual disease (MRD), detected through circulating tumor HPV DNA (ctHPVDNA), was associated with a higher risk of disease progression. When considered along with pathologic factors, postoperative ctHPVDNA assessment may improve patient selection for adjuvant treatment de-escalation; however, more data are needed to demonstrate how it may be used in personalizing treatment intensity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To determine the association of postoperative MRD status with progression-free survival (PFS) after surgery for HPV-associated oropharyngeal squamous cell carcinoma.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>This was a secondary analysis of the DART RCT, which was conducted from October 2016 to August 2020 in multiple sites in the US. Participants from the de-escalated adjuvant radiation therapy group and the standard of care group with available blood specimen data were included. Reports from 3-month posttreatment surveillance visits were used to assess associations and outcomes. Data analyses were performed from March 2023 to March of 2025.<\/jats:p><\/jats:sec><jats:sec><jats:title>Interventions<\/jats:title><jats:p>The DART group received 30 to 36 Gy of radiation therapy in 1.5 to 1.8 Gy twice daily, plus docetaxel, 15 mg\/m<jats:sup>2<\/jats:sup>, on days 1 and 8. The standard of care group received 60 Gy\u2009with or without\u2009weekly cisplatin, 40 mg\/m<jats:sup>2<\/jats:sup>.<\/jats:p><\/jats:sec><jats:sec><jats:title>Main Outcome and Measure<\/jats:title><jats:p>PFS.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The analysis included 140 patients (mean [SD] age, 59.1 [8.4] years; 12 [8.6%] females and 128 [91.4%] males; 97 [69.3%] with no smoking history); characteristics were similar to the overall DART RCT population. Of these, 17 patients (12.1%) had postoperative MRD (13 of 96 [13.5%] receiving DART and 4 of 44 [9.1%] receiving standard of care). For all patients, postoperative MRD positivity was strongly associated with worsened PFS at 24 months (MRD positivity, 69.5%; MRD negativity, 95.9%; hazard ratio [HR], 0.19; 95% CI, 0.06-0.59). MRD positivity was associated with PFS when evaluating only those patients in the DART group, where 24-month PFS was 68.4% compared to 92.6% for MRD-negative patients (HR, 0.28; 95% CI, 0.08-0.93). Three months after completion of all treatment, 8 of 117 patients (6.8%) had detectable ctHPVDNA, whereas 109 of 117 (93.2%) did not, and detection was highly associated with PFS (HR, 20.48; 95% CI, 6.91-60.67).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions and Relevance<\/jats:title><jats:p>This secondary analysis of the DART RCT found that patients with detectable ctHPVDNA after surgery had a higher risk of disease progression. When added to the pathologic factors considered, ctHPVDNA assessment may improve selection of patients for treatment de-escalation. In addition, the 3-month posttreatment time point, early in surveillance, may identify a sizable portion of patients with progression and may guide intervention and surveillance after surgery for HPV-associated oropharyngeal squamous cell carcinoma.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial Registration<\/jats:title><jats:p>ClinicalTrials.gov Identifier: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02908477\">NCT02908477<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamaoto.2025.0903","type":"journal-article","created":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T11:31:05Z","timestamp":1747913465000},"page":"665","source":"Crossref","is-referenced-by-count":18,"title":["ctDNA and Recurrence Risk for Adjuvant De-Escalation in HPV-Positive Oropharyngeal Carcinoma"],"prefix":"10.1001","volume":"151","author":[{"given":"David M.","family":"Routman","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn M.","family":"Van Abel","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology, Head and Neck Surgery, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharine A.","family":"Price","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric J.","family":"Moore","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology, Head and Neck Surgery, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir H.","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Mayo Clinic, Phoenix, Arizona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael L.","family":"Hinni","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology, Mayo Clinic, Phoenix, Arizona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Briant","family":"Fruth","sequence":"additional","affiliation":[{"name":"Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan R.","family":"Foster","sequence":"additional","affiliation":[{"name":"Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda X.","family":"Yin","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology, Head and Neck Surgery, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Neben-Wittich","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yolanda I.","family":"Garces","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa A.","family":"McGee","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Mayo Clinic, Phoenix, Arizona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott C.","family":"Lester","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauricio E.","family":"Gamez","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Claude M.","family":"Rwigema","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Mayo Clinic, Phoenix, Arizona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam L.","family":"Holtzman","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Mayo Clinic, Jacksonville, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel L.","family":"Price","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology, Head and Neck Surgery, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey R.","family":"Janus","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology, Head and Neck Surgery, Mayo Clinic, Jacksonville, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan L.","family":"Kasperbauer","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology, Head and Neck Surgery, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish V.","family":"Chintakuntlawar","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Mayo Clinic, Phoenix, Arizona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaquin J.","family":"Garcia","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine & Pathology, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L.","family":"Foote","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"224","key":"ooi250019r1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3007094","article-title":"Detection of circulating tumor DNA in early- and late-stage human malignancies.","volume":"6","author":"Bettegowda","year":"2014","journal-title":"Sci Transl Med"},{"issue":"5","key":"ooi250019r2","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/nm.3519","article-title":"An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage.","volume":"20","author":"Newman","year":"2014","journal-title":"Nat Med"},{"issue":"35","key":"ooi250019r3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.78.9032","article-title":"Circulating tumor DNA-defined minimal residual disease in solid tumors: opportunities to accelerate the development of adjuvant therapies.","volume":"36","author":"Dasari","year":"2018","journal-title":"J Clin Oncol"},{"issue":"12","key":"ooi250019r4","doi-asserted-by":"publisher","first-page":"2968","DOI":"10.1158\/2159-8290.CD-21-0634","article-title":"Detecting liquid remnants of solid tumors: circulating tumor DNA minimal residual disease.","volume":"11","author":"Moding","year":"2021","journal-title":"Cancer Discov"},{"issue":"6","key":"ooi250019r5","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1200\/JCO.21.01929","article-title":"Circulating tumor DNA minimal residual disease detection of non-small-cell lung cancer treated with curative intent.","volume":"40","author":"Pellini","year":"2022","journal-title":"J Clin Oncol"},{"issue":"12","key":"ooi250019r6","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1001\/jamaoto.2022.3282","article-title":"Association of pretreatment circulating tumor tissue-modified viral HPV DNA with clinicopathologic factors in HPV-positive oropharyngeal cancer.","volume":"148","author":"Rettig","year":"2022","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"issue":"2","key":"ooi250019r7","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1097\/PPO.0000000000000437","article-title":"Circulating tumor DNA Biomarkers for early detection of oligometastasis.","volume":"26","author":"Routman","year":"2020","journal-title":"Cancer J"},{"issue":"3","key":"ooi250019r8","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.ijrobp.2022.02.012","article-title":"Detectable postoperative circulating tumor human papillomavirus DNA and association with recurrence in patients with HPV-associated oropharyngeal squamous cell carcinoma.","volume":"113","author":"Routman","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"ooi250019r9","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1158\/1078-0432.CCR-21-3151","article-title":"Cell-Free HPV DNA provides an accurate and rapid diagnosis of hpv-associated head and neck cancer.","volume":"28","author":"Siravegna","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"19","key":"ooi250019r10","doi-asserted-by":"publisher","first-page":"4292","DOI":"10.1158\/1078-0432.CCR-22-0562","article-title":"Detection of occult recurrence using circulating tumor tissue modified viral HPV DNA among patients treated for HPV-driven oropharyngeal carcinoma.","volume":"28","author":"Berger","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"10","key":"ooi250019r11","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1200\/JCO.19.02444","article-title":"Plasma circulating tumor HPV DNA for the surveillance of cancer recurrence in HPV-associated oropharyngeal cancer.","volume":"38","author":"Chera","year":"2020","journal-title":"J Clin Oncol"},{"issue":"20","key":"ooi250019r12","doi-asserted-by":"publisher","first-page":"4306","DOI":"10.1158\/1078-0432.CCR-23-1478","article-title":"Negative predictive value of circulating tumor tissue modified viral (TTMV)-HPV DNA for HPV-driven oropharyngeal cancer surveillance.","volume":"29","author":"Hanna","year":"2023","journal-title":"Clin Cancer Res"},{"key":"ooi250019r13","first-page":"OF1","article-title":"Prospective trial of biomarker-guided surveillance for HPV-positive oropharynx cancer using plasma tumor tissue modified viral HPV DNA.","author":"Rettig","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"24","key":"ooi250019r14","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1056\/NEJMoa2200075","article-title":"Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer.","volume":"386","author":"Tie","year":"2022","journal-title":"N Engl J Med"},{"issue":"11","key":"ooi250019r15","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1002\/cncr.34109","article-title":"Cell-free human papillomavirus DNA kinetics after surgery for human papillomavirus-associated oropharyngeal cancer.","volume":"128","author":"O\u2019Boyle","year":"2022","journal-title":"Cancer"},{"issue":"6","key":"ooi250019r16","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1001\/jamaoto.2024.0740","article-title":"Circulating tumor HPV DNA in patients with stage I and II HPV-associated head and neck cancer after surgery.","volume":"150","author":"Naegele","year":"2024","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"issue":"9","key":"ooi250019r17","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1200\/JCO.20.03128","article-title":"Reduced-dose radiation therapy for HPV-associated oropharyngeal carcinoma (NRG Oncology HN002).","volume":"39","author":"Yom","year":"2021","journal-title":"J Clin Oncol"},{"issue":"4","key":"ooi250019r18","doi-asserted-by":"publisher","DOI":"10.1016\/j.adro.2022.100926","article-title":"The Number of radiographically positive lymph nodes further stratifies patient survival among clinical N1 patients with human papillomavirus-associated oropharyngeal cancer.","volume":"7","author":"Kowalchuk","year":"2022","journal-title":"Adv Radiat Oncol"},{"key":"ooi250019r19","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2021.105625","article-title":"Correlation between radiographic and pathologic lymph node involvement and extranodal extension via CT and PET in HPV-associated oropharyngeal cancer.","volume":"123","author":"Kowalchuk","year":"2021","journal-title":"Oral Oncol"},{"issue":"5","key":"ooi250019r20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2024.02.003","article-title":"Early disease recurrence following post-operative HPV ctDNA directed active surveillance in oropharyngeal carcinoma: outcomes of a prospective pilot study.","volume":"118","author":"Chen","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"ooi250019r21","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1016\/j.ijrobp.2017.06.2453","article-title":"Relapse rates with surgery alone in human papillomavirus-related intermediate- and high-risk group oropharynx squamous cell cancer: a multi-institutional review.","volume":"99","author":"Routman","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"22","key":"ooi250019r22","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1200\/JCO.19.00463","article-title":"Phase II evaluation of aggressive dose de-escalation for adjuvant chemoradiotherapy in human papillomavirus-associated oropharynx squamous cell carcinoma.","volume":"37","author":"Ma","year":"2019","journal-title":"J Clin Oncol"},{"issue":"2","key":"ooi250019r23","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.ijrobp.2022.05.047","article-title":"Long-term toxic effects, swallow function, and quality of life on MC1273: a phase 2 study of dose de-escalation for adjuvant chemoradiation in human papillomavirus-positive oropharyngeal cancer.","volume":"114","author":"Price","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"ooi250019r24","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1200\/JCO.21.01752","article-title":"Phase II randomized trial of transoral surgery and low-dose intensity modulated radiation therapy in resectable p16+ locally advanced oropharynx cancer: an ECOG-ACRIN Cancer Research Group Trial (E3311).","volume":"40","author":"Ferris","year":"2022","journal-title":"J Clin Oncol"},{"issue":"7","key":"ooi250019r25","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1158\/1078-0432.CCR-23-1789","article-title":"Sensitive MRD detection from lymphatic fluid after surgery in HPV-associated oropharyngeal cancer.","volume":"30","author":"Earland","year":"2024","journal-title":"Clin Cancer Res"}],"container-title":["JAMA Otolaryngology\u2013Head &amp; Neck Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaotolaryngology\/articlepdf\/2834560\/jamaotolaryngology_routman_2025_oi_250019_1752092946.19546.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T15:00:37Z","timestamp":1752159637000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaotolaryngology\/fullarticle\/2834560"}},"subtitle":["A Secondary Analysis of the DART Phase 3 Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":25,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoto.2025.0903","relation":{},"ISSN":["2168-6181"],"issn-type":[{"value":"2168-6181","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7,1]]}}}